Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm focusing on novel small molecule therapeutics for immune-mediated diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, at 12:00 pm ET in New York, NY.
Chris Kirk, Co-founder and CEO of Kezar, will deliver a corporate overview during the presentation. Investors and interested parties can access a live webcast of the presentation through the "Events & Presentations" section on Kezar's official website. An archived version of the webcast will remain available on the site for 90 days following the event, providing extended access to the company's latest updates and strategic outlook.
Kezar Life Sciences (Nasdaq: KZR), una società biotech in fase clinica che si concentra su nuovi farmaci a piccole molecole per malattie mediato dal sistema immunitario, ha annunciato la sua partecipazione al 26° Congresso Annuale Globale di Investimenti H.C. Wainwright. L'evento si svolgerà il 11 settembre 2024 alle 12:00 ET a New York, NY.
Chris Kirk, co-fondatore e CEO di Kezar, presenterà una panoramica aziendale durante la presentazione. Gli investitori e gli interessati possono accedere a un webcast dal vivo della presentazione attraverso la sezione
Kezar Life Sciences (Nasdaq: KZR), una empresa biotecnológica en etapa clínica enfocada en nuevos tratamientos de pequeñas moléculas para enfermedades mediadas por el sistema inmunológico, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento está programado para el 11 de septiembre de 2024 a las 12:00 pm ET en Nueva York, NY.
Chris Kirk, cofundador y CEO de Kezar, ofrecerá una visión general de la empresa durante la presentación. Los inversores y partes interesadas podrán acceder a un webcast en vivo de la presentación a través de la sección
Kezar Life Sciences (Nasdaq: KZR)는 면역 매개 질환을 위한 새로운 소분자 치료제에 집중하는 임상 단계의 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 11일 오후 12시 ET에 뉴욕에서 개최될 예정입니다.
Kezar의 공동 창립자이자 CEO인 Chris Kirk는 발표 중 기업 개요를 제공할 것입니다. 투자자와 관심 있는 사람들은 Kezar 공식 웹사이트의
Kezar Life Sciences (Nasdaq: KZR), une société biopharmaceutique en phase clinique axée sur de nouveaux traitements à petites molécules pour les maladies médiées par le système immunitaire, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement est prévu pour le 11 septembre 2024 à 12h00 ET à New York, NY.
Chris Kirk, co-fondateur et PDG de Kezar, présentera un aperçu de l'entreprise lors de la présentation. Les investisseurs et les parties intéressées pourront accéder à un webinaire en direct de la présentation via la section
Kezar Life Sciences (Nasdaq: KZR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neuartige kleine Molekültherapeutika für immunvermittelte Erkrankungen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung ist für den 11. September 2024 um 12:00 Uhr ET in New York, NY, geplant.
Chris Kirk, Mitbegründer und CEO von Kezar, wird während der Präsentation einen Unternehmensüberblick geben. Investoren und Interessierte können über die Rubrik
- None.
- None.
A webcast of the presentation will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904911170/en/
Investor and Media Contact:
Gitanjali Jain
Senior Vice President, Investor Relations and External Affairs
Kezar Life Sciences, Inc.
gjain@kezarbio.com
Source: Kezar Life Sciences, Inc.
FAQ
When is Kezar Life Sciences (KZR) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Kezar Life Sciences (KZR) at the investment conference?
How can investors access Kezar Life Sciences' (KZR) presentation at the conference?
How long will the archived webcast of Kezar Life Sciences' (KZR) presentation be available?
